Together, these data strongly support that tau-lowering ASOs that are currently in a clinical trial for Alzheimer’s disease may be able to rescue neuronal and astrocyte functions in neurodegenerative disease. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.